SPEXIS N overview

Spexis AG / Key word(s): Miscellaneous Spexis announces closing of sale of preclinical antibiotics program to Basilea 08-Feb-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, February 8, 2024 Spexis announces closing of sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program...

Spexis AG / Key word(s): Disposal Spexis announces sale of preclinical antibiotics program to Basilea 15-Jan-2024 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, January 15, 2024 Spexis announces sale of preclinical antibiotics program to Basilea Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics...

Spexis AG / Key word(s): Miscellaneous Spexis is Granted Debt-Restructuring Moratorium 05-Dec-2023 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Spexis is Granted Debt-Restructuring Moratorium Allschwil, Switzerland, December 5, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and...

Spexis AG / Key word(s): Miscellaneous Spexis Provides Update Regarding Debt-Restructuring Moratorium 29-Nov-2023 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Spexis Provides Update Regarding Debt-Restructuring Moratorium Allschwil, Switzerland, November 29, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle...

Spexis AG / Key word(s): Strategic Company Decision Spexis to file an application for a debt-restructuring moratorium 08-Nov-2023 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, November 8, 2023 Spexis to file an application for a debt-restructuring moratorium Spexis AG (SIX: SPEX) is in the process of filing an application for a...

Spexis AG / Key word(s): Personnel/Personnel Spexis Announces Changes to the Executive Committee 01-Nov-2023 / 07:20 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR Spexis Announces Changes to the Executive Committee Allschwil, Switzerland, November 1, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer, has decided to pursue a new career opportunity outside the company. He will continue to support the company as a strategic advisor on financial transactions and will depart the company effective...